Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.

Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.
PET Clin. 2018 Oct;13(4):491-503
Authors: Ahmadzadehfar H, Essler M, Rahbar K, Afshar-Oromieh A
Abstract
The skeleton is a common site for cancer metastases. Bone metastases are a major cause of morbidity and mortality and associated with pain, pathologic fractures, spinal cord compression, and decreased survival. Various radionuclides have been used for pain therapy. Recently, an α-emitter has been shown to improve overall survival of patients with bone metastases from castration-resistant prostate cancer and was approved as a therapeutic agent. The aim of this article is to provide an overview regarding state of the art radionuclide therapy options for bone metastases, with focus on the role of PET imaging in therapy planning.
PMID: 30219184 [PubMed - in process]

Source: Clinical Prostate Cancer - September 18, 2018 Category: Cancer & Oncology Authors: Ahmadzadehfar H, Essler M, Rahbar K, Afshar-Oromieh A Tags: PET Clin Source Type: research